308 related articles for article (PubMed ID: 10825042)
1. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.
Kaul R; McGeer A; Norrby-Teglund A; Kotb M; Schwartz B; O'Rourke K; Talbot J; Low DE
Clin Infect Dis; 1999 Apr; 28(4):800-7. PubMed ID: 10825042
[TBL] [Abstract][Full Text] [Related]
2. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.
Sriskandan S; Ferguson M; Elliot V; Faulkner L; Cohen J
J Antimicrob Chemother; 2006 Jul; 58(1):117-24. PubMed ID: 16670109
[TBL] [Abstract][Full Text] [Related]
3. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.
Norrby-Teglund A; Kaul R; Low DE; McGeer A; Newton DW; Andersson J; Andersson U; Kotb M
J Immunol; 1996 Apr; 156(8):3057-64. PubMed ID: 8609429
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.
Linnér A; Darenberg J; Sjölin J; Henriques-Normark B; Norrby-Teglund A
Clin Infect Dis; 2014 Sep; 59(6):851-7. PubMed ID: 24928291
[TBL] [Abstract][Full Text] [Related]
5. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.
Darenberg J; Söderquist B; Normark BH; Norrby-Teglund A
Clin Infect Dis; 2004 Mar; 38(6):836-42. PubMed ID: 14999628
[TBL] [Abstract][Full Text] [Related]
6. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome.
Schrage B; Duan G; Yang LP; Fraser JD; Proft T
Clin Infect Dis; 2006 Sep; 43(6):743-6. PubMed ID: 16912949
[TBL] [Abstract][Full Text] [Related]
7. A survey of physician's attitudes regarding management of severe group A streptococcal infections.
Valiquette L; Low DE; Chow R; McGeer AJ
Scand J Infect Dis; 2006; 38(11-12):977-82. PubMed ID: 17148064
[TBL] [Abstract][Full Text] [Related]
8. Diffuse venous thromboemboli associated with IVIg therapy in the treatment of streptococcal toxic shock syndrome: case report and review.
Geller JL; Hackner D
Ann Hematol; 2005 Sep; 84(9):601-4. PubMed ID: 15815906
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.
Darenberg J; Ihendyane N; Sjölin J; Aufwerber E; Haidl S; Follin P; Andersson J; Norrby-Teglund A;
Clin Infect Dis; 2003 Aug; 37(3):333-40. PubMed ID: 12884156
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review.
Perez CM; Kubak BM; Cryer HG; Salehmugodam S; Vespa P; Farmer D
Am J Med; 1997 Jan; 102(1):111-3. PubMed ID: 9209207
[No Abstract] [Full Text] [Related]
11. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach.
Norrby-Teglund A; Muller MP; Mcgeer A; Gan BS; Guru V; Bohnen J; Thulin P; Low DE
Scand J Infect Dis; 2005; 37(3):166-72. PubMed ID: 15849047
[TBL] [Abstract][Full Text] [Related]
12. Toxic shock syndrome due to group A streptococcal pharyngitis and bacteremia in an adult.
Vucicevic Z; Bencic IJ; Kruslin B; Degoricija V
J Microbiol Immunol Infect; 2008 Aug; 41(4):351-4. PubMed ID: 18787744
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery.
Buda S; Riefolo A; Biscione R; Goretti E; Cattabriga I; Grillone G; Bacchi-Reggiani L; Pacini D
J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):440-5. PubMed ID: 16085247
[TBL] [Abstract][Full Text] [Related]
14. [The role of IVIG in treatment of generalized infections].
Lewandowicz-Uszyńska A
Postepy Hig Med Dosw; 2002; 56 Suppl():85-90. PubMed ID: 12661418
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections.
Norrby-Teglund A; Ihendyane N; Darenberg J
Scand J Infect Dis; 2003; 35(9):683-9. PubMed ID: 14620155
[TBL] [Abstract][Full Text] [Related]
16. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome.
Eriksson BK; Andersson J; Holm SE; Norgren M
J Infect Dis; 1999 Aug; 180(2):410-8. PubMed ID: 10395857
[TBL] [Abstract][Full Text] [Related]
17. Streptococcal Toxic Shock Syndrome Caused by Group G Streptococcus, United Kingdom.
Baxter M; Morgan M
Emerg Infect Dis; 2017 Jan; 23(1):127-129. PubMed ID: 27983491
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome.
Shah SS; Hall M; Srivastava R; Subramony A; Levin JE
Clin Infect Dis; 2009 Nov; 49(9):1369-76. PubMed ID: 19788359
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
20. Puerperal widespread pyomyositis after group A streptococcal toxic shock syndrome.
Feigenberg T; Sela HY; Applbaum YH; Mankuta D
Isr Med Assoc J; 2008 Jun; 10(6):483-4. PubMed ID: 18669156
[No Abstract] [Full Text] [Related]
[Next] [New Search]
